XILIO THERAPEUTICS INC. - COMMON STOCK

Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting

23 Apr 2025 16:30:00 By Nasdaq GlobeNewswire

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Apr 2025 16:30:00 By Nasdaq GlobeNewswire

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results

11 Mar 2025 07:30:58 By Nasdaq GlobeNewswire

Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

24 Feb 2025 16:30:00 By Nasdaq GlobeNewswire

Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs

12 Feb 2025 07:35:00 By Nasdaq GlobeNewswire

AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

12 Feb 2025 07:33:00 By Nasdaq GlobeNewswire

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Feb 2025 16:30:00 By Nasdaq GlobeNewswire

Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer

21 Jan 2025 17:05:00 By Nasdaq GlobeNewswire

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

17 Jan 2025 16:30:00 By Nasdaq GlobeNewswire

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

10 Jan 2025 17:00:00 By Nasdaq GlobeNewswire

Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI 

19 Dec 2024 07:30:00 By Nasdaq GlobeNewswire

Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer

16 Dec 2024 07:30:00 By Nasdaq GlobeNewswire

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Dec 2024 16:30:00 By Nasdaq GlobeNewswire

Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors

07 Nov 2024 09:15:00 By Nasdaq GlobeNewswire

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results

07 Nov 2024 09:05:00 By Nasdaq GlobeNewswire

Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

30 Oct 2024 09:01:00 By Nasdaq GlobeNewswire

Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

04 Oct 2024 09:05:00 By Nasdaq GlobeNewswire

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Oct 2024 16:15:03 By Nasdaq GlobeNewswire

Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

28 Aug 2024 16:01:00 By Nasdaq GlobeNewswire

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results

08 Aug 2024 07:30:00 By Nasdaq GlobeNewswire